Thymocyte-fate decisions: bittersweet new flavor ----------------------------------------------------------------------------------------------------------------Guy Werlen RUTGERS UNIVERSITY
In this issue of Blood, Liu and colleagues demonstrate a novel mechanism for regulation of thymocyte-fate decisions by which a sugar-binding protein, galectin-1, enforces death while opposing survival of developing thymocytes. T he immune system's central tolerance is shaped in part in the thymus during T-cell development. Negative selection removes overtly autoreactive thymocytes, while positive selection promotes survival and development of self-tolerant T cells. Ligand binding to the Tcell receptor (TCR) controls both cell-fate decisions. 1 High-affinity agonists are thought to induce thymocyte death during negative selection, or to promote the generation of regulatory T cells such as the CD8␣␣ intestinal intraepithelial lymphocytes (IELs). 1, 2 On the other hand, partial agonists with low or moderate affinities trigger positive selection and thymocyte differentiation into T-helper or cytotoxic lineages. 1 Liu and colleagues add a new flavor to this mechanism by demonstrating that a particular lectin, galectin-1 (gal-1), contributes to discriminating TCR-controlled fate decisions by promoting the association of the TCR and its ligand.
This regulatory mechanism enforces agonist-driven signals leading to negative selection, while opposing partial agonist-induced thymocyte survival. gal-1 is a member of a family of ␤-galactose binding proteins that, by crosslinking cell-surface receptors, influence fate decisions in a variety of cells and tissues. 3, 4 Relevant to T-cell ontogeny, thymic cortical epithelial cells that present antigens to thymocytes also express gal-1. 3 This suggests a role for gal-1 in thymocytefate decisions. Liu and coauthors have investigated this question by using 2 distinct MHC class Irestricted, TCR-transgenic mouse models bearing a targeted deletion of gal-1. Ablating gal-1 markedly increased positive selection in these mouse models, while negative selection was decreased. Augmented positive selection correlated with a higher number of functional CD8 T cells in the spleens of gal-1 Ϫ/Ϫ TCR-transgenic animals. Interestingly, Liu and colleagues found a higher degree of ERK activation in the postselection thymocytes of gal-1 Ϫ/Ϫ mice. This result might explain the augmented positive selection observed in the absence of gal-1. Indeed, the intracellular kinase ERK is required for transducing TCR-triggered thymocyte-fate decision signals, and its distinct kinetics of activation represent a specific signature for positive and negative selection. 1 From their findings, the authors conclude that endogenous gal-1 opposes partial agonist-driven positive selection of conventional CD8 T cells by lowering the degree of ERK activation. It will be interesting to document, in the future, whether gal-1 modulates the kinetics of TCR partial agonist-driven ERK activation, as well as other TCR-linked signaling molecules such as the ERK-related kinase, JNK.
Nonetheless, Liu and colleagues demonstrate that by enhancing the association of agonist ligands to the TCR, gal-1 increases the magnitude of the fast and transient ERK activation signature that is characteristic for negative selection. Thus, by enforcing agonist-driven signal transduction, gal-1 promotes the removal of potentially autoreactive thymocytes from the repertoire. Interestingly, the authors found that gal-1 also promotes the selection of CD8␣␣ IELs. These regulatory T cells preferentially migrate to the gut after positive selection on TCR agonists instead of partial agonists. 2 Surprisingly, the authors observed a significant increase of CD8␣␣ IELs in the absence of gal-1 and in the context of TCR partial agonists. This might reflect a means by which gal-1 can influence the control of selection of T cells bearing autoreactive potential. However, additional work needs to be done to determine whether CD8␣␣ IELs can be selected by partial agonists, or whether these ligands simply promote better peripheral homing of CD8␣␣ IELs in the absence of gal-1. Nonetheless, Liu and colleagues highlight a novel mechanism for gal-1 contribution to central tolerance via shaping the reservoir of CD8 T cells. This might lead to novel therapeutic strategies in which the addition, or specific blocking, of gal-1 could be used as a unique tool to fine-tune the development of T cells with For personal use only. on April 14, 2017. by guest www.bloodjournal.org From maximal utility. In this regard, it is noteworthy that the administration of gal-1 successfully removed autoreactive T cells from a model of experimental multiple sclerosis. 5 Conflict-of-interest disclosure: The author declares no competing financial interests. ■
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Urokinase: the identity crisis continues ----------------------------------------------------------------------------------------------------------------Steven L. Gonias UNIVERSITY OF CALIFORNIA AT SAN DIEGO
Although urokinase-type plasminogen activator (uPA) was first identified due to its role in fibrinolysis, new studies increasingly uncover novel mechanisms by which uPA may regulate cell physiology. In this issue of Blood, Stepanova and colleagues demonstrate that binding of single-chain uPA to nucleolin facilitates nuclear translocation of uPA and promotes expression of smooth muscle ␣-actin (␣-SMA).
I n many multidomain proteases, exosites regulate protease activity by facilitating zymogen activation, controlling reaction with inhibitors, and localizing the protease with substrates. However, in some proteases, the enzyme active site may be regulatory, and the principal function may be something other than peptide-bond hydrolysis. uPA was first identified as 1 of 2 major mammalian plasminogen activators. The function of uPA in fibrinolysis is supported by the observation that simultaneous deletion of the genes for uPA and tissue-type plasminogen activator (tPA) in mice causes more severe thrombosis than tPA deletion alone. 1 The activity of uPA is intimately linked with that of its primary cell-surface receptor, uPAR. uPA-binding to uPAR, which requires the Nterminal EGF-like domain in uPA, mobilizes a cascade of cell-surface proteases that may support cell migration and tissue remodeling. Furthermore, uPA-binding to uPAR triggers cell signaling to factors such as ERK/MAP kinase and Akt. 2 Regulation of cell signaling downstream of uPAR has been implicated in cell migration, cell survival, gene transcription, and processes integral to cancer progression, such as epithelial-mesenchymal transition. 3 The lowdensity lipoprotein receptor-related protein (LRP-1) functions as a second uPA receptor, albeit with lower affinity. The principal function of LRP-1 in regulating uPA probably involves endocytosis and catabolism; however, LRP-1 also controls cell signaling in response to uPA-Serpin complexes. 4 The interaction of single-chain uPA with nucleolin, as described by Stepanova and colleagues, represents a novel pathway by which uPA may regulate cell physiology. Their biochemical and imaging studies provide compelling evidence that nucleolin shuttles intact single-chain uPA to the nucleus. Nuclear translocation of uPA appears to be necessary for regulating the expression of ␣-SMA, a marker of myofibroblasts implicated in processes such as pulmonary fibrosis and atherosclerosis. 5 Thus, in a manner reminiscent of thrombin, the interaction of uPA with cells may involve a menu of receptors and pathways. Based on K D values, one might argue that binding of uPA to uPAR should be favored; however, biochemistry occurring at the cell surface is not an equilibrium system, and many high-affinity interactions are dominated by slow off-rate constants.
How might the pathway selected by uPA be regulated? The authors show that mild acidification decreases the binding affinity of uPA for uPAR almost 10-fold while increasing the binding affinity for nucleolin. They argue that this shift may favor uPA association with nucleolin in endosomes. Although this is plausible, one must also consider the extracellular tumor microenvironment and its propensity for acidification. 6 Finally, the fact that 2-chain uPA does not localize to the nucleus emphasizes the importance of understanding various regions in the structure of uPA that are cleaved by plasmin, converting single-chain uPA into 2-chain uPA, highmolecular-weight uPA into low-molecularweight uPA, and deleting the EGF-like domain. 7 These reactions may play a pivotal role in controlling how uPA affects cell physiology.
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